DK173592B1 - Rekombinant viral ekspressionsvektor, som er i stand til i en transformant hvirveldyrcellekultur at udtrykke en DNA-sekvens - Google Patents
Rekombinant viral ekspressionsvektor, som er i stand til i en transformant hvirveldyrcellekultur at udtrykke en DNA-sekvens Download PDFInfo
- Publication number
- DK173592B1 DK173592B1 DK198203869A DK386982A DK173592B1 DK 173592 B1 DK173592 B1 DK 173592B1 DK 198203869 A DK198203869 A DK 198203869A DK 386982 A DK386982 A DK 386982A DK 173592 B1 DK173592 B1 DK 173592B1
- Authority
- DK
- Denmark
- Prior art keywords
- hbsag
- dna
- vector
- cell culture
- viral
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title claims description 21
- 241000251539 Vertebrata <Metazoa> Species 0.000 title claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 13
- 239000013604 expression vector Substances 0.000 title claims description 13
- 230000003612 virological effect Effects 0.000 title claims description 13
- 210000004027 cell Anatomy 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 20
- 239000002609 medium Substances 0.000 claims description 19
- 241000282693 Cercopithecidae Species 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 208000002672 hepatitis B Diseases 0.000 claims description 15
- 108091081024 Start codon Proteins 0.000 claims description 12
- 108091026890 Coding region Proteins 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000013519 translation Methods 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 108700005077 Viral Genes Proteins 0.000 claims description 2
- 108010067390 Viral Proteins Proteins 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 113
- 239000013612 plasmid Substances 0.000 description 43
- 239000012634 fragment Substances 0.000 description 35
- 241000700721 Hepatitis B virus Species 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 229920001184 polypeptide Polymers 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 18
- 241000700605 Viruses Species 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000010076 replication Effects 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 208000006454 hepatitis Diseases 0.000 description 13
- 231100000283 hepatitis Toxicity 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 108020004511 Recombinant DNA Proteins 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 230000004543 DNA replication Effects 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 101150061166 tetR gene Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241001426117 Crane hepatitis B virus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 101150023545 gel1 gene Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 101150054405 hpcH gene Proteins 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200100192A DK200100192A (da) | 1981-08-31 | 2001-02-06 | Vaccine mod hepatitis B-virus hos mennesker |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29823581A | 1981-08-31 | 1981-08-31 | |
| US29823581 | 1981-08-31 | ||
| US32698081A | 1981-12-03 | 1981-12-03 | |
| US32698081 | 1981-12-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK386982A DK386982A (da) | 1983-03-01 |
| DK173592B1 true DK173592B1 (da) | 2001-04-09 |
Family
ID=26970555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198203869A DK173592B1 (da) | 1981-08-31 | 1982-08-30 | Rekombinant viral ekspressionsvektor, som er i stand til i en transformant hvirveldyrcellekultur at udtrykke en DNA-sekvens |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP0291586A3 (no) |
| JP (3) | JPS5856685A (no) |
| AU (2) | AU555575B2 (no) |
| BR (1) | BR8205078A (no) |
| DE (1) | DE3280310D1 (no) |
| DK (1) | DK173592B1 (no) |
| ES (1) | ES515260A0 (no) |
| GB (1) | GB2105344B (no) |
| GR (1) | GR76906B (no) |
| HK (1) | HK29689A (no) |
| HU (1) | HU196238B (no) |
| IE (1) | IE53873B1 (no) |
| IL (1) | IL66637A (no) |
| KE (1) | KE3838A (no) |
| NO (1) | NO165598C (no) |
| NZ (1) | NZ201706A (no) |
| ZW (1) | ZW18282A1 (no) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196194A (en) * | 1979-05-24 | 1993-03-23 | The Regents Of The University Of California | Vaccines containing Hepatitis B S-protein |
| US4769238A (en) | 1981-08-04 | 1988-09-06 | The Regents Of The University Of California | Synthesis of human virus antigens by yeast |
| ZW18282A1 (en) | 1981-08-31 | 1983-03-23 | Genentech Inc | Preparation of polypeptides in vertebrate cell culture |
| JPS5936698A (ja) * | 1982-08-20 | 1984-02-28 | Science & Tech Agency | Ｂ型肝炎ウイルス遺伝子を組込んだ組換えｄｎａおよび形質転換動物細胞 |
| CA1209501A (en) * | 1982-09-16 | 1986-08-12 | Nikos Panayotatos | Expression vector |
| US4820642A (en) * | 1983-04-04 | 1989-04-11 | The Regents Of The University Of California | Amplified expression vector |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
| US7264817B1 (en) | 1983-08-30 | 2007-09-04 | Genentech, Inc. | Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it |
| EP0140762A1 (fr) * | 1983-10-03 | 1985-05-08 | Transgene S.A. | Vecteurs d'expression d'une proteine antigenique de la rage dans les cellules eucaryotes et leur application à la préparation d'un vaccin |
| FR2552776B1 (fr) * | 1983-10-03 | 1986-05-09 | Transgene Sa | Vecteurs d'expression d'une proteine antigenique de la rage dans les cellules eucaryotes et leur application a la preparation d'un vaccin |
| JPS6078999A (ja) * | 1983-10-05 | 1985-05-04 | Chemo Sero Therapeut Res Inst | ＨＢｓ抗原の精製方法 |
| US5639639A (en) * | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
| US5118627A (en) * | 1984-02-27 | 1992-06-02 | Amgen | Papova virus construction |
| FR2560890B1 (fr) * | 1984-03-07 | 1987-10-16 | Grp Genie Genetique | Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention |
| US4777240A (en) * | 1984-03-08 | 1988-10-11 | Scripps Clinic And Research Foundation | SV40 expression vector containing HBxAg as an expression marker |
| US4855224A (en) * | 1984-03-09 | 1989-08-08 | Genentech, Inc. | Molecularly cloned diagnostic product and method of use |
| US4663281A (en) * | 1984-03-22 | 1987-05-05 | Mass Institute Of Technology | Enhanced production of proteinaceous materials in eucaryotic cells |
| FR2564106B1 (fr) * | 1984-05-09 | 1988-04-22 | Transgene Sa | Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix. |
| US5683688A (en) * | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| WO1986006405A1 (en) * | 1985-05-02 | 1986-11-06 | Takeda Chemical Industries, Ltd. | Novel transformant and its use |
| EP0213628A3 (en) * | 1985-09-03 | 1988-09-21 | Yeda Research And Development Company, Ltd. | Expression of superoxide dismutase in eukaryotic cells |
| SE8505027D0 (sv) * | 1985-10-24 | 1985-10-24 | Kabigen Ab | A lytic virulent phage, a hostcell containing same and a process for protein production |
| KR950001993B1 (ko) * | 1985-12-18 | 1995-03-08 | 마이크로제네시스,인코포레이티드 | B형 간염 표면항원의 제조방법 |
| AU582288B2 (en) * | 1986-03-07 | 1989-03-16 | Damon Biotech Inc. | Vector and method for achieving high level expression in eukaryotic cells |
| US5004693A (en) * | 1986-07-18 | 1991-04-02 | E. I. Du Pont De Nemours And Company | Pseudorabies virus recombinants and their use in the production of proteins |
| NZ219516A (en) * | 1987-02-10 | 1991-02-26 | Wellcome Found | Fusion proteins of hbcag (hepatitis b virus core antigen) |
| US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
| US5443964A (en) * | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5578468A (en) * | 1987-08-10 | 1996-11-26 | Duke University | Site-specific RNA cleavage |
| JPH01285196A (ja) * | 1988-05-11 | 1989-11-16 | Chisso Corp | 発光蛋白エクオリンの製造法 |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| JP4085231B2 (ja) | 2000-02-28 | 2008-05-14 | 株式会社ビークル | タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3636191A (en) * | 1969-10-08 | 1972-01-18 | Cancer Res Inst | Vaccine against viral hepatitis and process |
| US4164565A (en) * | 1975-03-14 | 1979-08-14 | New York Blood Center, Inc. | Vaccine for active immunization containing hepatitis B surface antigen and associated antigen |
| FR2480779B2 (fr) * | 1979-08-30 | 1986-07-18 | Anvar | Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur |
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| DD147855A5 (de) * | 1978-12-22 | 1981-04-22 | Biogen Nv | Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids |
| IE52036B1 (en) | 1979-05-24 | 1987-05-27 | Univ California | Non-passageable viruses |
| JPS5610119A (en) * | 1979-07-05 | 1981-02-02 | Alpha Therapeutic Corp | Manufacture of b type hepatitis infection preventive vaccine |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811895B (en) * | 1980-04-07 | 1982-04-28 | Univ California | Expression of hormone genomic clones |
| EP0038765B1 (fr) * | 1980-04-22 | 1987-09-02 | Institut Pasteur | Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin |
| FR2480780B1 (fr) * | 1980-04-22 | 1985-12-06 | Pasteur Institut | Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn |
| EP0062574A3 (en) * | 1981-03-31 | 1982-12-29 | The Regents Of The University Of California | Virus protein synthesis |
| JPS5813598A (ja) * | 1981-06-22 | 1983-01-26 | イーライ・リリー・アンド・カンパニー | 組み替えｄｎａクロ−ニング・ベクタ−ならびにその真核細胞性および原核細胞性被形質転換体 |
| NZ201705A (en) * | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| ZW18282A1 (en) | 1981-08-31 | 1983-03-23 | Genentech Inc | Preparation of polypeptides in vertebrate cell culture |
| US4442205A (en) * | 1981-09-22 | 1984-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | Simian virus recombinant that directs the synthesis of hepatitis B surface antigen |
| AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| FR2521165A1 (fr) * | 1982-02-08 | 1983-08-12 | Pasteur Institut | Fragments d'adn codant pour un peptide immunogene susceptible d'introduire in vivo la synthese d'anticorps anti-poliovirus |
| US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
-
1982
- 1982-08-06 ZW ZW182/82A patent/ZW18282A1/xx unknown
- 1982-08-25 NZ NZ201706A patent/NZ201706A/en unknown
- 1982-08-25 IL IL66637A patent/IL66637A/xx not_active IP Right Cessation
- 1982-08-26 GB GB08224527A patent/GB2105344B/en not_active Expired
- 1982-08-26 DE DE8282304512T patent/DE3280310D1/de not_active Revoked
- 1982-08-26 ES ES515260A patent/ES515260A0/es active Granted
- 1982-08-26 EP EP87202618A patent/EP0291586A3/en not_active Withdrawn
- 1982-08-26 EP EP82304512A patent/EP0073656B1/en not_active Revoked
- 1982-08-27 IE IE2084/82A patent/IE53873B1/en not_active IP Right Cessation
- 1982-08-27 AU AU87798/82A patent/AU555575B2/en not_active Expired
- 1982-08-30 DK DK198203869A patent/DK173592B1/da not_active IP Right Cessation
- 1982-08-30 BR BR8205078A patent/BR8205078A/pt unknown
- 1982-08-30 HU HU822777A patent/HU196238B/hu unknown
- 1982-08-30 JP JP57150627A patent/JPS5856685A/ja active Granted
- 1982-08-30 NO NO822926A patent/NO165598C/no not_active IP Right Cessation
- 1982-08-30 GR GR69154A patent/GR76906B/el unknown
-
1986
- 1986-08-20 AU AU61671/86A patent/AU589673B2/en not_active Expired
-
1988
- 1988-10-25 KE KE3838A patent/KE3838A/xx unknown
-
1989
- 1989-04-06 HK HK296/89A patent/HK29689A/xx not_active IP Right Cessation
-
1993
- 1993-07-30 JP JP5189904A patent/JP2634371B2/ja not_active Expired - Lifetime
-
1995
- 1995-08-07 JP JP7201034A patent/JP2726641B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES8401134A1 (es) | 1983-12-01 |
| JPH06261748A (ja) | 1994-09-20 |
| HU196238B (en) | 1988-10-28 |
| IE822084L (en) | 1983-02-28 |
| JPH0937777A (ja) | 1997-02-10 |
| AU6167186A (en) | 1987-01-08 |
| AU589673B2 (en) | 1989-10-19 |
| BR8205078A (pt) | 1983-08-09 |
| NO165598B (no) | 1990-11-26 |
| EP0073656A3 (en) | 1984-10-24 |
| DK386982A (da) | 1983-03-01 |
| IL66637A (en) | 1991-11-21 |
| ZW18282A1 (en) | 1983-03-23 |
| IE53873B1 (en) | 1989-03-29 |
| AU555575B2 (en) | 1986-10-02 |
| KE3838A (en) | 1988-12-02 |
| EP0291586A2 (en) | 1988-11-23 |
| NO822926L (no) | 1983-03-01 |
| GR76906B (no) | 1984-09-04 |
| EP0073656B1 (en) | 1991-03-06 |
| AU8779882A (en) | 1983-03-10 |
| NZ201706A (en) | 1986-05-09 |
| DE3280310D1 (de) | 1991-04-11 |
| JP2726641B2 (ja) | 1998-03-11 |
| HK29689A (en) | 1989-04-14 |
| GB2105344B (en) | 1985-10-09 |
| EP0291586A3 (en) | 1988-12-07 |
| EP0073656A2 (en) | 1983-03-09 |
| JP2634371B2 (ja) | 1997-07-23 |
| IL66637A0 (en) | 1982-12-31 |
| JPS5856685A (ja) | 1983-04-04 |
| JPH0587518B2 (no) | 1993-12-16 |
| GB2105344A (en) | 1983-03-23 |
| NO165598C (no) | 1991-03-06 |
| ES515260A0 (es) | 1983-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK173592B1 (da) | Rekombinant viral ekspressionsvektor, som er i stand til i en transformant hvirveldyrcellekultur at udtrykke en DNA-sekvens | |
| JP2511394B2 (ja) | 酵母菌中でのｂ型肝炎表面抗原の製造 | |
| JP2610015B2 (ja) | アデノウイルスプロモーターの制御下で所定のポリペプチドをコードしているヌクレオチド配列を含む組換えｄｎａ | |
| US5314808A (en) | Method for the transformation of cells, particularly eukaryotes by a DNA originating from viruses of hepatitis, more particularly from virus of a B viral hepatitis, and preparations containing the expression products of said DNAs | |
| EP0244924B1 (en) | Production of vaccines against Hepatitis B virus | |
| JPH0884588A (ja) | ヘテロポリマー系蛋白質 | |
| NO304268B1 (no) | FremgangsmÕte for fremstilling av et protein med aminosyresekvens som bestÕr av deler av aminosyre-sekvensen til hepatitt B-virus-stort (L) protein, vertscelle transformert med DNA som koder for proteinet, samt anvendelse av et protein eventuelt | |
| EP0101617A2 (en) | Recombinant DNA containing a hepatitis B virus gene, mammalian cells transformed with the cloned viral DNA, and production of hepatitis B virus proteins | |
| DK166357B (da) | Partikler med immunogene egenskaber svarende til hbs antigen samt vektorer og animalske celler til produktion af saadanne partikler | |
| JPH08308575A (ja) | 組換アデノウイルス | |
| US4741901A (en) | Preparation of polypeptides in vertebrate cell culture | |
| CA1222707A (en) | Preparation of hepatitis b virus vaccine | |
| Stenlund et al. | Secretion of the hepatitis B virus surface antigen from mouse cells using an extra‐chromosomal eucaryotic vector. | |
| JPH0314840B2 (no) | ||
| Stratowa et al. | Recombinant retroviral DNA yielding high expression of hepatitis B surface antigen. | |
| ES2264183T3 (es) | Metodo para obtener antigeno de superficie del virus de la hepatitis b (hep b), recombinante, con capacidad inmunogenica superior y su uso en una preparacion de vacuna. | |
| EP0105141A2 (en) | Recombinant DNA molecules, process for their production, their use for production of hepatitis B surface antigen (HBsAg) and pharmaceutical compositions containing this HBsAg | |
| Denniston et al. | Expression of hepatitis B virus surface and e antigen genes cloned in bovine papillomavirus vectors | |
| JPS61500971A (ja) | Ｂ型肝炎ウイルスの表面抗原と重合ヒト血清アルブミンレセプタ−とを有する粒子を含むワクチン製造に有用な組成物、前記の如き粒子を産生し得る動物細胞、並びにこれら細胞を得るための方法 | |
| AU4315689A (en) | Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders | |
| NO885658L (no) | Retrovirusekspresjonsvektorer og fremgangsmaater for fremstilling av hbv-antigener. | |
| EP0257507A1 (en) | Hepatitis vaccine | |
| PT85108B (pt) | Virus da varicela-zoster util como vacina viva recombinante | |
| DK173671B1 (da) | Fremgangsmåde til selektion af transficerede hvirveldyrceller | |
| Marquardt | Hepatitis B virus components produced by the human hepatoma cell line PLC/PRF/5: Do they indicate virus propagation? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PUP | Patent expired |